Romania Pharmaceuticals and Healthcare Report Q2 2016

77 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: In line with Romania’s economic outperformance in Europe, the country’s pharmaceutical and
healthcare markets will see strong growth given increased consumer spending power and higher healthcare
contributions. However, aggressive drug pricing regulations, including the imminent joint drug
procurement agreement with Bulgaria will limit revenue earning opportunities.
Headline Expenditure Projections
? Pharmaceuticals: RON14.94bn (USD3.73bn) in 2015 to RON16.16bn (USD3.91bn) in 2016; 8.2% in
local currency terms and 4.9% in US dollar terms.
? Healthcare: RON33.84bn (USD8.45bn) in 2015 to RON34.95bn (USD8.46bn) in 2016; 3.3% in local
currency terms and 0.2% in US dollar terms.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Romania 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Romania 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Romania 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Romania 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Romania 2012-2020) 16
Prescription Drug Market Forecast 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Romania 2012-2020) 18
Patented Drug Market Forecast 19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Romania 2012-2020) 20
Generic Medicine Market Forecast 21
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Romania 2012-2020) 23
OTC Medicine Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Romania 2012-2020) 26
Pharmaceutical Trade Forecast 27
Table: Pharmaceutical Trade Data And Forecasts (Romania 2014-2020) 28
Table: Pharmaceutical Trade Data And Forecasts local currency (Romania 2014-2020) 28
Pharmaceuticals & Healthcare Risk/Reward Index 29
Central And Eastern Europe Risk/Reward Index 29
Romania Risk/Reward Index 35
Rewards 35
Risks 36
Regulatory Review 37
Intellectual Property Issues 37
Corruption 38
Pricing Regime 39
Reimbursement Regime 40
Market Overview 44
Healthcare System 45
Table: Healthcare Resources (Romania 2010-2015) 48
Table: Healthcare Personnel (Romania 2010-2015) 48
Table: Healthcare Activity (Romania 2010-2015) 49
Research And Development 49
Clinical Trials 50
Epidemiology 51
Competitive Landscape 54
Research-Based Industry 54
Table: Members Of ARPIM, 2016 54
Table: Multinational Market Activity 55
Generic Drugmakers 56
Pharmaceutical Distribution 57
Pharmaceutical Retail Sector 57
Company Profile 59
Antibiotice Iasi 59
LaborMed Pharma 62
Terapia Ranbaxy 64
Demographic Forecast 66
Table: Population Headline Indicators (Romania 1990-2025) 67
Table: Key Population Ratios (Romania 1990-2025) 67
Table: Urban/Rural Population & Life Expectancy (Romania 1990-2025) 68
Table: Population By Age Group (Romania 1990-2025) 68
Table: Population By Age Group % (Romania 1990-2025) 69
Glossary 71
Methodology 73
Pharmaceutical Expenditure Forecast Model 73
Healthcare Expenditure Forecast Model 73
Notes On Methodology 74
Risk/Reward Index Methodology 75
Index Overview 76
Table: Pharmaceutical Risk/Reward Index Indicators 76
Indicator Weightings 77

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Romania 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Romania 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Romania 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Romania 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Romania 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Romania 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Romania 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Romania 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Romania 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Romania 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Romania 2014-2020)
Table: Healthcare Resources (Romania 2010-2015)
Table: Healthcare Personnel (Romania 2010-2015)
Table: Healthcare Activity (Romania 2010-2015)
Table: Members Of ARPIM, 2016
Table: Multinational Market Activity
Table: Population Headline Indicators (Romania 1990-2025)
Table: Key Population Ratios (Romania 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Romania 1990-2025)
Table: Population By Age Group (Romania 1990-2025)
Table: Population By Age Group % (Romania 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Bulgaria Pharmaceuticals and Healthcare Report Q4 2015BMI View: Strong pharmaceutical sales growth in 2015 will be moderated over the medium term by cost containment measures. Healthcare payers in Central and Eastern Europe will become increasingly assertive in using their purchasing power to demand discounts from drugmakers in order to contain rising healthcare costs. The announcement of a joint procurement drive with Romania will increase pricing pressures on pharmaceutical manufacturers over the long term. Headline Expenditure […]
  • Bulgaria Pharmaceuticals and Healthcare Report Q1 2016BMI View: Pharmaceutical companies in Bulgaria will face increased pricing pressures from the National Health Insurance Fund (NHIF) as it unveils more cost-containment measures to rein in pharmaceutical expenditure. The NHIF will increasingly leverage its purchasing power to negotiate with drugmakers, and this dynamic will moderate the growth outlook for the country's pharmaceutical sector. Headline Expenditure Projections ? Pharmaceuticals: BGN2.53bn (USD1.72bn) in 2014 to BGN2.71bn […]
  • Bulgaria Pharmaceuticals and Healthcare Report Q2 2016BMI View: Bulgaria's healthcare sector is in need of reform to improve its efficiency; however, it is likely to see spending cuts as the government must enforce strong cost-saving measures to reduce the budget deficit. Such controls to healthcare spending will produce a bleak outlook for pharmaceutical and healthcare providers. Headline Expenditure Projections ? Pharmaceuticals: BGN2.71bn (USD1.52bn) in 2015 to BGN2.89bn (USD1.58bn) in 2016; +6.7% in local currency terms and +3.8% in […]
  • Moldova Pharmaceuticals and Healthcare Report Q2 2016BMI View: Moldova's pharmaceutical market presents very limited opportunities for multinational drugmakers, in comparison to its neighbours in Eastern Europe. The country's small total market size and its reliance on out-of-pocket payments highlight the challenges it poses. Moldova's economic outlook, which is defined by its relations with Russia and the EU, will play a significant role in how the market grows over the coming years. Headline Expenditure Projections ? Pharmaceuticals: […]
  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality […]

arrowStay In Touch

RSS